Trial Profile
A phase I, open-label multi-center, dose escalation study of AMN107 [nilotinib] in combination with imatinib in adult patients with Ph+ chronic myelogenous leukemia in chronic phase following a sub-optimal response to imatinib mesylate
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 01 Aug 2006
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary) ; Imatinib
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Pharmacogenomic
- 01 Aug 2006 New trial record.